Ceribell (NASDAQ: CBLL) is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.

Building, deploying, and scaling Ceribell's core seizure platform (wearables, firmware, software, and algorithms) to reduce clinician admin burden, decrease time from EEG recording to evaluation, and drive efficient revenue capture.

Built and deployed an EHR-integrated AI co-pilot for front-line clinicians that identifies and supports the treatment of the highest-risk sepsis patients.

Raising the standard of care of SUD by launching a clinical care platform and patient mobile apps to increase access to care, improve engagement in care, and improve quality of care delivery.

Real World Evidence and Digital Biomarkers -- built and deployed mobile tools and wearable devices in Verily and partner clinical studies aiming to capture real world measures for prediction of mental illness (i.e. depression, anxiety, and PTSD).